Evaluation of the levels of CDK-5, interlukin-2 and another biochemical parameter for patients with breast cancer in Baghdad city

Women with breast cancer who took part in this study were classified into pre and post-menopausal. Postmenopausal women comprised two-thirds of the healthy, recently diagnosed, and treated groups. Non-obese, overweight, and obese women were categorized according to their body mass index (BMI). A significant correlation a p-value of less than 0.05, patients have lower leukocyte numbers, lymphocytes counts, monocyte counts, and basophil counts than the control group. Cdk5 protein levels in recently diagnosed women with breast cancer rise disproportionately to treatment (63 percent of 40 treated patients have a low rate of CDK-5 (17.2 ± 4.90). Cdk5 protein levels increased by 50% in the tumor specimens of 30 patients. Tumor samples from 50 newly diagnosed patients with breast cancer were tested for IL-2 protein levels for the first time, and the results showed that 80 percent of the 40 treated patients had a low level of IL-2 900 ± 191.90 compared to 90 percent of those who had previously been affected by the disease. As a result of this study, a statistical link was found between the newly diagnosed (NMB) and normal breasts' total estradiol concentrations (1111.73 ± 170.5, 494.9 ± 129, 614.72 ± 180.08, respectively).